Sign in →

Test ID ELYME Lyme Disease European Antibody Screen, Serum


Advisory Information


This test should only be ordered for patients who present with Lyme disease symptoms and who have recently returned from travel to Europe or Asia. These patients may be infected with Lyme disease causing Borrelia species endemic to Europe (eg, B afzelii, B garinii), which may not be detected using diagnostic tests in North America. The North American serologic assays for Lyme disease are developed specifically for detection of antibodies to B burgdorferi (strain B31), the most commonly encountered species.

 

Patients who are suspected to have Lyme disease who have not traveled to Europe should be tested by the LYME / Lyme Disease Serology, Serum assay for detection of antibodies specifically to Borrelia burgdorferi, the most common agent of Lyme disease in North America.



Specimen Required


Supplies: Aliquot Tube, 5 mL (T465)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: 5-mL aliquot tube (T465)

Specimen Volume: 0.5 mL

Pediatric: 0.5 mL


Forms

If not ordering electronically, complete, print, and send a Microbiology Test Request (T244) with the specimen.

Useful For

Aids in diagnosis of Lyme disease caused by infection with Borrelia species endemic to Europe and Asia, including B garinii and B afzelii.

 

This test is only intended for use in patients with recent travel to and exposure to ticks in Europe or regions of Asia who are suspected to have Lyme disease caused by Borrelia species endemic to Europe/Asia.

Highlights

The first-tier screening assay detects antibodies to the VlsE protein. C6 is a conserved epitope in the VlsE protein. Therefore, this assay will detect antibodies to C6, in addition to other epitopes on VlsE and pepC10.

 

This test should be ordered for evaluation of possible Lyme disease in individuals who have recently traveled to  Europe or Asia and who have been exposed to or bitten by a tick.

 

This panel includes a screening test capable of detecting antibodies to the most common Lyme disease causing Borrelia species found in Europe and Asia. Specimens with positive or equivocal results by the screening assay will be reflexed to a supplemental immunoblot able to detect antibodies to B afzelii or B garinii, both Lyme disease-causing Borrelia species endemic to Europe and regions of Asia.

 

The immunoblot does not distinguish between infection with B afzelli or B garinii.

 

Patients infected with B afzelii or B garinii may be serologically negative by diagnostic assays used in North America, which are designed to detect antibodies to the B burgdorferi B31 strain.

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
ELYMI Lyme Disease European Immunoblot, S No No

Testing Algorithm

If this test is positive or equivocal, then immunoblot testing will be performed at an additional charge.

 

See Acute Tick-Borne Disease Testing Algorithm in Special Instructions.

Method Name

Enzyme-Linked Immunosorbent Assay (ELISA)

Reporting Name

Lyme Disease European Ab Screen, S

Specimen Type

Serum

Specimen Minimum Volume

0.4 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 10 days
  Frozen  30 days

Reference Values

Negative

Day(s) and Time(s) Performed

Monday through Friday; 10 a.m.

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86618

86617 x 2 - Lyme Disease European Immunoblot, S (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
ELYME Lyme Disease European Ab Screen, S 57916-9

 

Result ID Test Result Name Result LOINC Value
ELYME Lyme Disease European Ab Screen, S 57916-9

NY State Approved

Yes